Truveta

This weekend at the International Society for Pharmacoepidemiology's Annual Meeting in Berlin, Truveta Research will be presenting a poster on whether the increased demand and subsequent shortages of GLP-1s for both type 2 diabetes and overweight/obesity patients has led to an increase in prescription switching among these medications. Learn more: https://tr.vet/4dwWNBy #ISPEAnnual2024 #ISPEAnnualMeeting #ISPEAnnualMeeting2024 #ICPE #ICPEAnnual2024 #ICPEAnnualMeeting2024 #ISPE #Pharmacoepidemiology #Berlin #tirzepatide #semaglutide #Mounjaro #Ozempic #WeightLoss #WeightLossMedication #WeightLossDrugs #PrescriptionTrends #GLP1s #HealthData #HealthcareData #HealthcareAI #HealthAI #AI #Innovation #HealthInnovation #HealthcareInnovation #MedicalData #MedicalAI #MedicalInnovation #MedicalTechnology #MedTech #EHRData #ElectronicHealthRecords

Ovarian cancer is exceptionally difficult to diagnose, and in urgent need of breakthrough research. With Truveta's wealth of data, researchers can advance diagnostics, support new therapy development, and improve patient outcomes. Learn more: https://tr.vet/3A35SDg #OvarianCancer #CancerResearch #HealthcareAI #HealthcareTech #HealthAI #HealthTech #AI #Innovation #HealthcareResearch #MedicalTechnology #MedTech #MedicalData #MedicalInnovation #MedicalAI #HealthcareResearch #HealthResearch

In GeekWire's latest Top 200 startups list, Truveta earned the highest spot among healthcare startups, and moved up 14 spots from the previous list. 🙌 Learn more: https://tr.vet/3WT7A1R #GeekWire #GeekWireTop200 #Top200 #TopStartups #PNWStartups #SeattleStartups #TechStartups

This summer, we had the honor of hosting representatives from healthcare, life sciences, and public health at our second annual Truveta Symposium. Presenters shared fascinating research studies and offered valuable insights into the positive impacts technology is having on healthcare and life sciences, and guests had a chance to network, brainstorm around shared research interests, and discuss future collaboration opportunities. We are so inspired by the creativity and passion our partners are pouring into our shared mission of Saving Lives with Data - and we're already looking forward to next year. Watch this short video for some of the highlights from our second annual Truveta Symposium!

In partnership with University of Pennsylvania Perelman School of Medicine Vice Provost Dr. Ezekiel Emanuel, MD, PhD, Truveta Research conducted the first-ever study on whether patients taking GLP-1s like semaglutide and tirzepatide showed trends of discontinuing and reinitiating these meds. Now available as a preprint on MedRxiv: https://tr.vet/3YM0q1X #PrePrint #PennMedical #PennMedicalResearch #GLP1Research #WeightLossDrugs #WeightLoss #Semaglutide #Tirzepatide #Wegovy #Ozempic #Mounjaro #Zepbound #HealthData #PrescriptionTrends #AI #Innovation #HealthAI #HealthInnovation #HealthTech #HealthcareData #HealthcareTech #MedicalTechnology #MedicalData #MedTech #PrePrint #MedicalResearch #HealthResearch #PrescriptionTrends

Our Co-founder and Chief Technical Officer Jay Nanduri knows that developing a great, scalable large language model (LLM) isn't a one-size-fits-all project. That's why he's constantly making strategic choices about the modeling technology, data, training/supervision effort, and knowledge retention policies we use in the Truveta Language Model, in order to develop solutions that serve each challenge in an optimal way. Learn more about how we're scaling our AI models for growth in Jay's latest blog: https://tr.vet/4deSQBo Catch up on the other posts in Jay's series on our AI journey: 🎯 Delivering accuracy and explainability for AI: https://tr.vet/3yszcmf 🧠 Avoiding bias: https://tr.vet/3XEu8p0 🪨 Generating data gravity: https://tr.vet/4cJUJWd 🛣️ Truveta's journey applying generative AI to advance healthcare: https://tr.vet/3RMtEJK

"A recent study by Truveta Research, in collaboration with Dr. Ezekiel Emanuel from the University of Pennsylvania Perelman School of Medicine, has uncovered insights into the patterns of discontinuation and reinitiation of GLP-1 receptor agonists (GLP-1 RAs). This research, which analyzed electronic health record (EHR) data from Truveta Data, focuses on a cohort of patients with overweight or obesity who started GLP-1 RA treatment between 2018 and 2023." Read more, via The Evidence Base®: https://tr.vet/4fFVPEE #GLP1s #GLP1Data #WeightLoss #WeightLossDrugs #Tirzepatide #Semaglutide #Liraglutide #T2DM #WeightLossTrends #PrescriptionTrends #PrescriptionData #HealthData #HealthTech #HealthInnovation #HealthAI #AI #Innovation #HealthcareTech #HealthcareData #HealthcareInnovation #HealthcareAI #MedicalTechnology #MedTech #MedicalData #MedicalAI #MedicalInnovation

Biologic medication #Humira, used to treat inflammatory conditions like arthritis, psoriasis, Crohn's disease, and more, is the highest-grossing medication in history. But, its 20-year market exclusivity ended in 2023, and now more than 10 biosimilars have been approved in the US. However, despite lower prices, sales data on biosimilars have shown low uptake. To encourage switching, CVS Pharmacy removed Humira from some formularies in favor of one of the less expensive biosimilars. Now, Truveta Research is examining whether uptake of biosimilars has increased since CVS's shift. Learn more: https://tr.vet/46CGAZ9 #InflammatoryConditions #Arthritis #CrohnsDisease #Psoriasis #DrugCosts #PrescriptionCosts #PrescriptionTrends #Biologic #Biosimilar #HealthData #HealthcareData #HealthInnovation #HealthAI #HealthcareInnovation #HealthcareData #AI #Innovation #MedicalTechnology #MedTech #MedicalData #MedicalAI #MedicalInnovation

In the latest in his series, our Co-founder and CTO Jay Nanduri shares the challenges of scaling AI technology to extract clinically relevant insights from EHR data - large patient populations, diversity of scenarios, and complex research questions. He discusses how we have created solutions to these challenges and tailored our AI models to unlock valuable information for clinical research and improve patient care in a cost-effective way. Read the full article here: https://tr.vet/3yszcmf And catch up on his other posts in this series: Avoiding bias: https://tr.vet/3XEu8p0 🪨 Generating data gravity: https://tr.vet/4cJUJWd 🛣️ Truveta's journey applying generative AI to advance healthcare: https://tr.vet/3RMtEJK #AI #healthcareAI #largelanguagemodel #healthdata #healthinnovation #scale #scalingAI #healthtech #healthcaretech #medicaltechnology #medtech #medicalAI #medicalinnovation #medicaldata #healthcaredata #digitaltransformation

Ovarian cancer is exceptionally difficult to diagnose, and in urgent need of breakthrough research. To help in this critical battle, Truveta offers the most complete, longitudinal cancer data across the continuum of care, including 21M encounters, 82M labs, and 1.1M imaging studies across 106K ovarian cancer patients. With this wealth of data, researchers can advance diagnostics, support new therapy development, and improve patient outcomes. Learn more about the ovarian cancer data available for research in Truveta Data: https://tr.vet/3A35SDg #OvarianCancer #Cancer #OvarianCancerResearch #CancerResearch #CancerData #OvarianCancerData #HealthData #HealthcareData #HealthcareInnovation #HealthcareAI #HealthAI #HealthInnovation #MedicalData #MedicalTechnology #MedTech #MedicalAI #MedicalInnovation #HealthResearch #MedicalResearch #HealthcareResearch